The labs help expand the research and development efforts for controlled release drugs and other technically difficult generic pharmaceutical products.
The premises have been expanded by about 300 sq metres and the new R&D labs have been expanded by about 140 sq metres.
Recently launched Actavis South Atlantic products in the United States include Bupropion, the generic equivalents of GlaxoSmithKline’s Wellbutrin as well as Nifedipine, the generic equivalent of Bayer’s Adalat.
“Actavis in the United States is focused on our vision and commitment to be on the cutting edge of new technology. The expansion of our South Atlantic R&D facility ensures that we remain well-positioned to develop and manufacture XL (extended release) and CR (continuous release) drugs,” said Doug Boothe, Actavis U.S. CEO.
Actavis is one of the leading companies in the U.S. market in the development of continuous release products, with more than EUR 50 million expected to be invested in their development in 2008.
The Florida investments are the latest in a spate of recent expansion news from Iceland-based Actavis reported on Euromech and elsewhere. The company also announced its formal launch onto the French generic pharmaceuticals market last week.